Lyell Immunopharma Announces Participation in September Investor Conferences
Lyell Immunopharma (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company, has announced its participation in two upcoming investor conferences in September 2024. The company's senior management team will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4th at 10:45 am ET and the H.C. Wainwright 26th Annual Global Investment Conference on September 9th at 8:30 am ET.
Lyell Immunopharma specializes in developing cell therapies for patients with solid tumors or hematologic malignancies. Interested parties can access live webcasts of the presentations through the Investors section of Lyell's website. Replays will be available on the company's website following each presentation.
Lyell Immunopharma (Nasdaq: LYEL), un'azienda in fase clinica specializzata nella riprogrammazione delle cellule T, ha annunciato la sua partecipazione a due prossimi conferenze per investitori a settembre 2024. Il team di gestione senior dell'azienda presenterà alla 22ª Conferenza Annuale sulla Sanità Globale di Morgan Stanley il 4 settembre alle 10:45 ET e alla 26ª Conferenza Annuale sugli Investimenti Globali di H.C. Wainwright il 9 settembre alle 8:30 ET.
Lyell Immunopharma è specializzata nello sviluppo di terapie cellulari per pazienti con tumori solidi o neoplasie ematologiche. Le parti interessate possono accedere alle dirette web delle presentazioni attraverso la sezione Investitori del sito web di Lyell. Le registrazioni saranno disponibili sul sito dell'azienda dopo ogni presentazione.
Lyell Immunopharma (Nasdaq: LYEL), una empresa en etapa clínica de reprogramación de células T, ha anunciado su participación en dos próximas conferencias para inversores en septiembre de 2024. El equipo de alta dirección de la empresa presentará en la 22ª Conferencia Anual de Salud Global de Morgan Stanley el 4 de septiembre a las 10:45 a.m. ET y en la 26ª Conferencia Anual de Inversiones Globales de H.C. Wainwright el 9 de septiembre a las 8:30 a.m. ET.
Lyell Immunopharma se especializa en desarrollar terapias celulares para pacientes con tumores sólidos o malignidades hematológicas. Las partes interesadas pueden acceder a las transmisiones en vivo de las presentaciones a través de la sección de Inversores del sitio web de Lyell. Las repeticiones estarán disponibles en el sitio web de la empresa después de cada presentación.
Lyell Immunopharma (Nasdaq: LYEL), 임상 단계 T세포 재프로그래밍 회사가 2024년 9월에 열리는 두 개의 투자자 컨퍼런스에 참여한다고 발표했습니다. 회사의 고위 경영진 팀은 9월 4일 오전 10시 45분 ET에 모건 스탠리 제22회 연례 글로벌 헬스케어 회의에서 발표할 예정이며, 9월 9일 오전 8시 30분 ET에 H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에서 발표할 예정입니다.
Lyell Immunopharma는 고형 종양이나 혈액 악성 종양 환자를 위한 세포 요법 개발을 전문으로 하고 있습니다. 관심 있는 분들은 Lyell의 웹사이트 투자자 섹션을 통해 프레젠테이션의 생중계를 접속할 수 있습니다. 프레젠테이션 후에는 회사 웹사이트에서 재생딜도 이용할 수 있습니다.
Lyell Immunopharma (Nasdaq: LYEL), une entreprise de reprogrammation des cellules T en phase clinique, a annoncé sa participation à deux prochaines conférences pour investisseurs en septembre 2024. L'équipe de direction de l'entreprise présentera à la 22ème Conférence Annuelle Mondiale sur la Santé de Morgan Stanley le 4 septembre à 10h45 ET et à la 26ème Conférence Annuelle Mondiale sur les Investissements de H.C. Wainwright le 9 septembre à 8h30 ET.
Lyell Immunopharma se spécialise dans le développement de thérapies cellulaires pour les patients atteints de tumeurs solides ou de maladies hématologiques. Les parties intéressées peuvent accéder aux retransmissions en direct des présentations via la section Investisseurs du site web de Lyell. Les rediffusions seront disponibles sur le site de l'entreprise après chaque présentation.
Lyell Immunopharma (Nasdaq: LYEL), ein Unternehmen für die Reprogrammierung von T-Zellen in der klinischen Phase, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 angekündigt. Das Führungsteam des Unternehmens wird am 4. September um 10:45 Uhr ET auf der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley präsentieren und am 9. September um 8:30 Uhr ET auf der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright.
Lyell Immunopharma ist auf die Entwicklung von Zelltherapien für Patienten mit soliden Tumoren oder hämatologischen Malignitäten spezialisiert. Interessierte Parteien können über den Investorenbereich der Webseite von Lyell auf die Live-Übertragungen der Präsentationen zugreifen. Nach jeder Präsentation werden Aufzeichnungen auf der Unternehmenswebsite verfügbar sein.
- Participation in high-profile investor conferences may increase visibility and investor interest
- Live webcasts of presentations indicate transparency and accessibility for investors
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, announced today that members of its senior management team will present and participate in the following upcoming investor conferences:
- Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th at 10:45 am Eastern Time
- H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9th at 8:30 am Eastern Time
A live webcast of the presentation can be accessed through the Investors section of the Company's website at www.lyell.com. Following the live presentation, a replay of the webcast will be available on the Company's website following the presentation date.
About Lyell
Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies, including three product candidates in or entering Phase 1 clinical development for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel anti-exhaustion technology designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. Lyell applies its proprietary ex vivo genetic and epigenetic reprogramming technology to address these barriers to develop new medicines with improved durable clinical outcomes. Lyell is based in South San Francisco, California with facilities in Seattle and Bothell, Washington. To learn more, please visit www.lyell.com.
Contact:
Ellen Rose
Senior Vice President, Communications and Investor Relations
erose@lyell.com
FAQ
When and where will Lyell Immunopharma (LYEL) present at the Morgan Stanley Global Healthcare Conference?
What is the date and time of Lyell Immunopharma's (LYEL) presentation at the H.C. Wainwright Global Investment Conference?
How can investors access Lyell Immunopharma's (LYEL) conference presentations?
What type of therapies is Lyell Immunopharma (LYEL) developing?
